Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 198 participants.

Also called NCT06364215

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 198 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06364215
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT06364215. Randomized; double masking; primary purpose treatment. Start 2024-10-08 (actual); primary completion 2025-11-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation
Acronym
(SMILE-AF)
Condition
Atrial Fibrillation Paroxysmal
Intervention (Device)
Farapulse PFA, Pulmonary Vein Isolation alone
Intervention (Device)
Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation
Lead sponsor
Jorge Romero (class: other)
Collaborator
Boston Scientific Corporation (class: industry)
Collaborator
Databean (class: industry)

Record details

Record id
cardio:ct-nct06364215
Content hash
0ed130256505f3d2cb9cc64f3375837ca719eb48ed057efb0e47c5a993e49e9f